Eagle Asset Management Inc. grew its stake in Celgene Corporation (NASDAQ:CELG) by 652.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,533 shares of the biopharmaceutical company’s stock after purchasing an additional 131,405 shares during the quarter. Eagle Asset Management Inc.’s holdings in Celgene Corporation were worth $19,679,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in CELG. Oaktop Capital Management II L.P. acquired a new stake in shares of Celgene Corporation in the second quarter valued at about $271,605,000. Harbour Capital Advisors LLC grew its position in shares of Celgene Corporation by 12,913.6% in the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after purchasing an additional 1,575,074 shares during the period. Investec Asset Management LTD acquired a new stake in shares of Celgene Corporation in the first quarter valued at about $194,490,000. Clearbridge Investments LLC grew its position in shares of Celgene Corporation by 24.1% in the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares during the period. Finally, State Street Corp lifted its stake in shares of Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Institutional investors and hedge funds own 79.39% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Eagle Asset Management Inc. Has $19.68 Million Position in Celgene Corporation (CELG)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/eagle-asset-management-inc-has-19-68-million-position-in-celgene-corporation-celg.html.
Celgene Corporation (NASDAQ:CELG) opened at $100.04 on Friday. The firm has a market cap of $78,763.20, a PE ratio of 15.63, a PEG ratio of 0.77 and a beta of 1.79. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm posted $1.58 earnings per share. Celgene Corporation’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current year.
Several research firms have recently weighed in on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price target (up from $148.00) on shares of Celgene Corporation in a research note on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 27th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a research note on Friday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and set a $160.00 target price (up from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $156.00 target price on shares of Celgene Corporation in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $139.64.
In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now owns 69,424 shares in the company, valued at $9,061,220.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 38,733 shares of company stock worth $5,259,359 in the last 90 days. 0.95% of the stock is currently owned by insiders.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.